References
- RogersSMcIntoshRLCheungNThe prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and AustraliaOphthalmology201011731331920022117
- KleinRKleinBEKLeeKECruickshanksKJGangnonREChanges in visual acuity in a population over a 15-year period: the Beaver Dam Eye StudyAm J Ophthalmol200614253153916935620
- KleinRMossSEMeuerSMKleinBEThe 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye StudyArch Ophthalmol200812651351818413521
- TurelloMPascaSDaminatoRRetinal vein occlusion: evaluation of “classic” and “emerging” risk factors and treatmentJ Thromb Thrombolysis20102945946419669864
- GreenWRChanCCHutchinsGMTerryJMCentral vein occlusion: a prospective histological study of 29 eyes in 28 casesTrans Am Ophthalmol Soc1981793714217342407
- The Branch Vein Occlusion Study GroupArgon laser photocoagulation for macular edema in branch vein occlusionAm J Ophthalmol1984982712826383055
- The Central Vein Occlusion Study GroupEvaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The central vein occlusion study group M reportOphthalmology1995102142514339097788
- FerraraNDamicoLShamsNLowmanHKimRDevelopment of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degenerationRetina20062685987017031284
- CampochiaroPAHafizGShahSMRanibizumab for macular edema due to retinal vein occlusions; implication of VEGF as a critical stimulatorMolec Ther20081679179918362932
- PieramiciDJRabenaMCastellarinAARanibizumab for the treatment of macular edema associated with perfused central retinal vein occlusionsOphthalmology20081154754
- SpaideRFChangLKKlancnikJMProspective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusionAm J Ophthalmol200914729830618929354
- BrownDMCampochiaroPASinghRPEfficacy and safety of ranibizumab in the treatment of macular edema secondary to central retinal vein occlusion: 6-month results of the phase III CRUISE studyOphthalmology20101171124113320381871
- CampochiaroPAHeierJSFeinerLRanibizumab for macular edema following branch retinal vein occlusion: 6-month primary endpoint results of a phase III studyOphthalmology20101171102111220398941
- CampochiaroPABrownDMAwhCCSustained benefits from ranibizumab for macular edema following central retinal vein occlusion: 12-month outcomes of a phase III studyOphthalmology2011In press
- BrownDMCampochiaroPABhisitkulRBSustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III studyOphthalmology2011In press
- CampochiaroPAHafizGChannaRAntagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusion: two-year outcomesOphthalmology20101172387239420630595
- The SCORE Study Research GroupA randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion. The standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 5Arch Ophthalmol20091271101111419752419
- The SCORE Study Research GroupA randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch vein occlusion. The standard care vs corticosteroid for retinal vein occlusion (SCORE) study report 6Arch Ophthalmol20091271115112819752420
- HallerJAKuppermannBDBlumenkranzMSRandomized controlled trial of an intravitreous dexamthasone drug delivery system in patients with diabetic macular edemaArch Ophthalmol201012828929620212197
- CampochiaroPAChoyDFDoDVMonitoring ocular drug therapy by analysis of aqueous samplesOphthalmology20091162158216419700195